Back to Cell Types

8305CHomo sapiens (Human)Cancer cell line

Also known as: 8305C_1, 8305-C, 8305c

🤖 AI SummaryBased on 10 publications

Quick Overview

Anaplastic thyroid cancer cell line with DUSP26 amplification and p38 inhibition

Detailed Summary

The 8305C cell line is an anaplastic thyroid cancer cell line derived from a human tumor. It exhibits amplification of the DUSP26 gene, which is known to promote cancer cell growth by inhibiting p38 MAPK activity. This cell line is characterized by its high expression of DUSP26, which contributes to its aggressive growth properties. The 8305C cell line has been used in studies to investigate the role of DUSP26 in cancer progression and its potential as a therapeutic target. Research on this cell line has also highlighted its utility in understanding the mechanisms of p38 MAPK inhibition and its implications in cancer biology.

Research Applications

Cancer biology researchDrug target identificationMAPK signaling pathway studies

Key Characteristics

DUSP26 amplificationp38 MAPK inhibitionAnaplastic thyroid cancer model

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1053
Species	Homo sapiens (Human)
Tissue Source	Thyroid gland[UBERON:UBERON_0002046]

Donor Information

Age	67
Age Category	Adult
Sex	Female

Disease Information

Disease	Anaplastic thyroid carcinoma
Lineage	Thyroid
Subtype	Anaplastic Thyroid Cancer
OncoTree Code	THAP

DepMap Information

Source Type	DSMZ
Source ID	ACH-001306_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg273Cys (c.817C>T)	Homozygous	-	PubMed=35933914
MutationSimple	TERT	c.1-146C>T (c.250C>T) (C250T)	Unspecified	In promoter	PubMed=31068700
MutationSimple	NRAS	p.Phe90Leufs*14 (c.270delT)	Heterozygous	-	PubMed=30737244
MutationSimple	BRAF	p.Val600Glu (c.1799T>A)	Unspecified	-	PubMed=26214590
MutationSimple	ATM	p.Gln2800Ter (c.8398C>T)	Heterozygous	-	Unknown, Unknown, PubMed=30737244

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

9,12

D13S317

9

D16S539

10,11

D18S51

13,24

D19S433

14

D21S11

30,32.2

D2S1338

17,25

D3S1358

15

D5S818

10,13

D7S820

8

D8S1179

11,14

FGA

21,22

Penta D

10

Penta E

15,17

TH01

6,7

TPOX

8

vWA

14,16

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.

Fagin J.A., Schweppe R.E.

Clin. Cancer Res. 25:3141-3151(2019).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

Ibrahimpasic T., Ghossein R.A., Fagin J.A.

J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Establishment of 2 human thyroid-carcinoma cell-lines (8305C, 8505C) bearing p53 gene-mutations.

Iwamoto K.S., Tsuyama N., Nakamura N., Akiyama M.

Int. J. Oncol. 4:583-586(1994).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity.

Yu W., Imoto I., Inoue J., Onda M., Emi M., Inazawa J.

Oncogene 26:1178-1187(2007).

Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes.

Mizutani K., Shimizu K., Nagahama M., Ito K., Tanaka T., Tsunoda T.

Endocr. Relat. Cancer 11:843-854(2004).

p73 tumor-suppressor activity is impaired in human thyroid cancer.";

Vigneri P.

Cancer Res. 63:5829-5837(2003).

Screening the p53 status of human cell lines using a yeast functional assay.

Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Mol. Carcinog. 19:243-253(1997).

Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines.

Satake S., Sugawara I., Watanabe M., Takami H.

Cancer Lett. 116:33-39(1997).